Skip to main navigation Skip to search Skip to main content

ATIM-08. TRIAL IN PROGRESS: CA209-9Y8 PHASE 2 TRIAL OF TUMOR TREATING FIELDS (TTFS), NIVOLUMAB PLUS/MINUS IPILIMUMAB FOR BEVACIZUMAB-NAÏVE, RECURRENT GLIOBLASTOMA

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalNeuro-oncology
Volume21
DOIs
StatePublished - Nov 11 2019

Disciplines

  • Oncology
  • Internal Medicine
  • Medicine and Health Sciences
  • Immunology and Infectious Disease

Cite this